News

ANAVEX 3-71 is a preclinical drug candidate with a novel mechanism of action through sigma-1 receptor activation and M1 muscarinic allosteric modulation, which has demonstrated to enhance neuroprotection

The companies formed an alliance in 2014 to develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor. The new milestone means Eli Lilly will pay

JW Biotechnology (Shanghai) Co., Ltd’s mission is to build China’s leading cell therapy company by leveraging Juno’s world-class chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies

MOR106 was jointly discovered by MorphoSys and Galapagos under their collaboration, and has a novel mode of action with potential application in inflammation. The primary objective of the

The IND is now active. This will be Adaptimmune’s second wholly-owned therapeutic candidate to enter clinical trials. The company initiated a study in December 2015 to evaluate its

The CHMP also noted that the importance of favourable effects of RUCONEST is further supported by the continued availability of supply of RUCONEST (produced by recombinant technology) in

The target date for the FDA to take action under the Prescription Drug User Fee Act is 29 May. If approved by FDA, the drug would be the

The approval expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies. Two formulations have been approved

The randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, phyarmacodynamics, and glucose and insulin dose-lowering properties of REMD-477 in up to 20 patients with type 1 diabetes